
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen Inc. has demonstrated a robust performance, with average selling prices (ASPs) for its testing products increasing to $441 per test, reflecting a year-over-year growth of 9%, indicating a positive trend in pricing strategy. The company's revenue has also seen a notable increase of 19% year-over-year on a nine-month basis, supported by balanced growth in both ASPs and test volumes, showcasing their effective market penetration among community rheumatologists. Furthermore, Exagen's strategic expansion plans—including an increase in sales territories and leadership changes within the commercial team—position the company well for sustained volume growth and operational success moving forward.
Bears say
Exagen Inc's stock outlook is negatively impacted by a revised growth forecast for 2026, which reflects delayed positive free cash flow and a decline in peer multiples, leading to a price target reduction from $18 to $8. The company experienced a significant stock drop of over 60% following the 3Q25 results, largely due to the loss of a direct bill account that represented 2% of total volume, raising concerns about overall growth and profitability timelines. Furthermore, Exagen has reduced its workforce by approximately 42 full-time equivalents across sales, R&D, and other functions, resulting in lower revenue per sales territory compared to previous quarters.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares